Selank 10mg

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a derivative of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide, with an added Pro-Gly-Pro sequence that confers enhanced metabolic stability and additional neurotropic activity. Selank is approved in Russia as an anxiolytic and nootropic medication. Selank's anxiolytic mechanism involves modulation of the GABAergic system. It has been shown to allosterically enhance GABA-A receptor function and influence the expression of the GABA transporter GAT-1 gene. Unlike benzodiazepines, selank does not produce sedation, amnesia, or dependence at anxiolytic doses. Research by Seredenin et al. demonstrated that selank's anxiolytic effect is comparable to benzodiazepines in standard behavioral tests (elevated plus maze, open field) without the characteristic side effects. Beyond anxiolysis, selank influences the expression of brain-derived neurotrophic factor (BDNF) and other neurotrophins. Gene expression studies have shown it affects over 50 genes related to neuronal signaling, inflammation, and immune function. Its immunomodulatory properties are inherited from the parent molecule tuftsin and include enhancement of phagocytic activity and modulation of T-helper cell responses, making selank unique among anxiolytic compounds in its dual neuroimmune activity.

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a derivative of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide, with an added Pro-Gly-Pro sequence that confers enhanced metabolic stability and additional neurotropic activity. Selank is approved in Russia as an anxiolytic and nootropic medication. Selank's anxiolytic mechanism involves modulation of the GABAergic system. It has been shown to allosterically enhance GABA-A receptor function and influence the expression of the GABA transporter GAT-1 gene. Unlike benzodiazepines, selank does not produce sedation, amnesia, or dependence at anxiolytic doses. Research by Seredenin et al. demonstrated that selank's anxiolytic effect is comparable to benzodiazepines in standard behavioral tests (elevated plus maze, open field) without the characteristic side effects. Beyond anxiolysis, selank influences the expression of brain-derived neurotrophic factor (BDNF) and other neurotrophins. Gene expression studies have shown it affects over 50 genes related to neuronal signaling, inflammation, and immune function. Its immunomodulatory properties are inherited from the parent molecule tuftsin and include enhancement of phagocytic activity and modulation of T-helper cell responses, making selank unique among anxiolytic compounds in its dual neuroimmune activity.

Russian clinical studies used intranasal doses of 250-500 mcg per day. Animal behavioral studies typically use 100-300 mcg/kg. Intranasal administration is the most common route studied.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.